Search results
Results from the WOW.Com Content Network
The cause for its tumbling share price was the announcement that starting in 2027, the biotech will slash its research and development (R&D) expenses by $1.1 billion. Its trailing-12-month R&D ...
Moderna's COVID vaccine sales have fallen off a cliff, with a revenue of just $241 million in the second quarter, down 30% from $344 million a year ago. It had $19.3 billion in total revenue for ...
September 14, 2024 at 4:20 AM. Moderna 's (NASDAQ: MRNA) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand for its ...
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in ...
In April 2020, with the Moderna share price rising on news of imminent phase 2 human trials for its potential COVID-19 vaccine, Bancel's stake of about 9% became worth over $1 billion. [4] He lives in Boston , Massachusetts.
In December 2018, Moderna became a public company via the largest initial public offering of a biotechnology company in history, raising $621 million by selling 27 million shares at $23 per share. [24] [25] The first mRNA vaccine developed by Moderna was for influenza in 2015, and its first antibody encoded by mRNA was in 2019. [6]
(List price for Moderna's COVID vaccine: $110.) So while the Moderna vaccines "are good for public health, it means you have to sell more to get to the same revenue," Hoge said.
(Reuters) -Moderna shares rose 8% to a three-month high on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in ...